Diagnosis of CML patients occurs principally in the chronic phase.
Since the introduction of the tyrosine kinase inhibitors (TKIs), patients seldom progress to the accelerated or blast phases. However, without treatment with TKIs, CML can be life-threatening.
Patients who remain in the chronic phase of CML have a similar life expectancy as the general population.
Up to 10% of patients receive their diagnosis when in the accelerated or blast phase of CML. This reduces their chance of a good outcome.
- Are in the chronic phase, but have not responded to at least two TKIs
- Are in the accelerated phase
- Are in the blast phase